Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation

Background: In the treatment of advanced urothelial (aUC) and renal cell carcinoma (aRCC), biomarkers such as PD-1 and PD-L1 are not robust prognostic markers for immunotherapy (IO) response. Previously, a significant association between IO and a change in splenic volume (SV) was described for sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Duwe, Gregor, Müller, Lukas, Ruckes, Christian, Fischer, Nikita Dhruva, Frey, Lisa Johanna, Börner, Jan Hendrik, Rölz, Niklas, Haack, Maximilian, Sparwasser, Peter, Jorg, Tobias, Neumann, Christopher C. M., Tsaur, Igor, Höfner, Thomas, Haferkamp, Axel, Hahn, Felix, Mager, Rene, Brandt, Maximilian Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526098/
https://www.ncbi.nlm.nih.gov/pubmed/37760923
http://dx.doi.org/10.3390/biomedicines11092482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526098/
https://www.ncbi.nlm.nih.gov/pubmed/37760923
http://dx.doi.org/10.3390/biomedicines11092482

Ejemplares similares